Board

Bo Kollberg

Chairman of the board (b. 1949)

Bo has been in the pharmaceutical industry for more than 40 years. For years he has held senior positions at GlaxoSmithKline (GSK) internationally, including VP at GSK Consumer Healthcare. Bo led the work of GSK's takeover of AstraZeneca's OTC portfolio and trademarks, such as Sensodyne, During Bo's time, Panodil and Alvedon have evolved into leading in their market segments. Bo has a degree in chemistry and biomedicine from Uppsala University.

Lars Lindström

Board member (b. 1964)

Lars has been in the pharmaceutical industry for 30 years. He is a chemistry engineer and has worked with research and development at Ferring for example. For years he was active in the field of chromatography, a technique that is central to NorInvent's research.

He has also worked a great deal of his professional life in sales of medical devices, including global sales responsibility for advanced analytical equipment. Between 2007 and 2014 Lars was the CEO of MKS Umetrics, a global software company.

Kristian Enkvist

Board member (b. 1960)

Kristian Enkvist, born 1960; life science and med tech professional with 20+ years’ experience of business development, innovation and product development. He has spent a large part of his career in industry (HemoCue, Gambro, PerkinElmer, Wallac, AstraZeneca) but also has experience as CEO (AcouSort AB, and presently POOW Application AB) and board member of startup companies (Kibron OY, Hydrogene AB). Kristian has a PhD in Biochemistry and is Adjunct Professor (sv. Docent) in Neurochemistry at Åbo Akademi University in Finland. In addition to managing POOW Applications, he is presently Business Development Officer at AcouSort AB and Advisor at SmiLe, the life science incubator in Lund.

Joel Karlsson

Board member (b. 1979)

Joel has been running innovation companies for a long time and, through his role as CEO, has been a driving force in securing capital needs for development and marketing. The company is today a fast growing public limited company with a number of shareholders.

He also has extensive experience in sales and development of IT products aimed at the financial market.